Quick MRI follow-up for liver cancer treatment
Part of Cancer, Digestive system clinical trials.
This trial tests if a shorter MRI scan can effectively monitor liver cancer after a procedure called TACE. If you've had TACE for liver cancer and have good liver function, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You've had a procedure called TACE for liver cancer that couldn't be removed surgically
- You are between 20 and 85 years old
- Your main liver blood vessel is open (no blockage) based on an ultrasound
- You have no fluid buildup in your belly (ascites)
- Your liver function is satisfactory (your doctor can confirm this)
- Your kidney function is good (a blood test shows eGFR of 60 or higher)
- You have no history of severe allergic reaction to contrast dye (used for some scans)
- You are not claustrophobic, don't have a cochlear implant or a cardiac pacemaker
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a shorter MRI using a special dye to a CT scan for detecting liver cancer recurrence in people who have been cancer-free for at least two years after surgery or local treatment.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
This study looks at ways to improve screening for liver cancer in adults with long-term liver disease. It may help catch liver cancer earlier, which can make treatment easier.
This trial studies a faster MRI scan to help track early liver cancer in people who have cirrhosis and are considered high risk. It may improve how often and how well doctors can look for changes without using longer imaging sessions.
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.